Generic Copaxone Availability

Copaxone is a brand name of glatiramer, approved by the FDA in the following formulation(s):

COPAXONE (glatiramer acetate - injectable;subcutaneous)

  • Manufacturer: TEVA PHARMS USA
    Approval date: February 12, 2002
    Strength(s): 20MG/ML [RLD]
  • Manufacturer: TEVA PHARMS USA
    Approval date: January 28, 2014
    Strength(s): 40MG/ML [RLD]

Has a generic version of Copaxone been approved?

No. There is currently no therapeutically equivalent version of Copaxone available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Copaxone. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Copolymer-1 improvements in compositions of copolymers
    Patent 5,981,589
    Issued: November 9, 1999
    Inventor(s): Konfino; Eliezer & Sela; Michael & Teitelbaum; Dvora & Arnon; Ruth
    Assignee(s): Yeda Research and Development Co., Ltd.
    The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
    Patent expiration dates:
    • May 24, 2014
  • Copolymer-1 improvements in compositions of copolymers
    Patent 6,054,430
    Issued: April 25, 2000
    Inventor(s): Konfino; Eliezer & Sela; Michael & Teitelbaum; Dvora & Arnon; Ruth
    Assignee(s): Yeda Research and Development Co., Ltd.
    The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
    Patent expiration dates:
    • May 24, 2014
      ✓ 
      Drug substance
    • May 24, 2014
  • Copolymer-1 improvements in compositions of copolymers
    Patent 6,342,476
    Issued: January 29, 2002
    Inventor(s): Eliezer; Konfino & Michael; Sela & Dvora; Teitelbaum & Ruth; Arnon
    Assignee(s): Yeda Research & Development Company Limited
    The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
    Patent expiration dates:
    • May 24, 2014
      ✓ 
      Patent use: METHOD OF TREATING MS BY ADMINISTERING COPAXONE
  • Copolymer-1 improvements on compositions of copolymers
    Patent 6,362,161
    Issued: March 26, 2002
    Inventor(s): Eliezer; Konfino & Michael; Sela & Dvora; Teitelbaum & Ruth; Arnon
    Assignee(s): Yeda Research & Development Company Limited
    The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
    Patent expiration dates:
    • May 24, 2014
      ✓ 
      Drug substance
    • May 24, 2014
      ✓ 
      Patent use: METHOD OF TREATING MS BY ADMINISTERING COPAXONE
  • Copolymer-1 improvements in compositions of copolymers
    Patent 6,620,847
    Issued: September 16, 2003
    Inventor(s): Eliezer; Konfino & Michael; Sela & Dvora; Teitelbaum & Ruth; Arnon
    Assignee(s): Yeda Research and Development Co., Ltd.
    The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
    Patent expiration dates:
    • May 24, 2014
      ✓ 
      Drug substance
  • Copolymer-1 improvements in compositions of copolymers
    Patent 6,939,539
    Issued: September 6, 2005
    Inventor(s): Konfino; Eliezer & Sela; Michael & Teitelbaum; Dvora & Arnon; Ruth
    Assignee(s): Yeda Research & Development
    The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
    Patent expiration dates:
    • May 24, 2014
      ✓ 
      Drug substance
  • Copolymer-1 improvements in compositions of copolymers
    Patent 7,199,098
    Issued: April 3, 2007
    Inventor(s): Konfino; Eliezer & Sela; Michael & Teitelbaum; Dvora & Arnon; Ruth
    Assignee(s): Yeda Research and Development Co., Ltd.
    The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
    Patent expiration dates:
    • May 24, 2014
      ✓ 
      Drug substance
  • Low frequency glatiramer acetate therapy
    Patent 8,232,250
    Issued: July 31, 2012
    Inventor(s): Klinger; Ety
    Assignee(s): Yeda Research & Development Co., Ltd.
    A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.
    Patent expiration dates:
    • August 19, 2030
      ✓ 
      Patent use: METHOD OF TREATING MS BY ADMINISTERING COPAXONE
  • Copolymer-1 improvements in compositions of copolymers
    Patent 8,367,605
    Issued: February 5, 2013
    Assignee(s): Yeda Research and Development Co. Ltd.
    The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
    Patent expiration dates:
    • May 24, 2014
      ✓ 
      Drug substance
  • Low frequency glatiramer acetate therapy
    Patent 8,399,413
    Issued: March 19, 2013
    Assignee(s): Yeda Research & Development Co., Ltd.
    A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.
    Patent expiration dates:
    • September 6, 2030
      ✓ 
      Patent use: METHOD OF TREATING MS BY ADMINISTERING COPAXONE

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • January 28, 2017 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web3)